The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment Approach for Children and Adolescents with Hodgkin Lymphoma ¹

Added Cvetković et al. as reference 18 ².

Added text ³ to state that adults and children treated for nodular lymphocyte-predominant Hodgkins lymphoma (NLPHL) usually have a favorable outcome when the disease is in its earlier stages. This has been shown by a retrospective study that included adults with NLPHL and that only 8 of 32 deaths were attributed directly to Hodgkin lymphoma. The current standard of therapy for children with NLPHL is chemotherapy with LD-IFRT. Some patients with isolated nodal disease are successfully treated with chemotherapy alone or resection alone. The largest experience in children with resection alone for NLPHL was reported by the European Network Group on Pediatric Hodgkin Lymphoma. In this report of 58 children, there was 100% survival with seven patients developed with recurrences (cited Karayalcin et al. , Nogová et al. , Diehl et al. , Sextro et al. , Mauz-Körholz et al. , Murphy et al. , Sandoval et al. , Miettinen et al. , and Hansmann et al. as references 28, 29, 30, 31, 32, 33, 34, and 35, respectively).

Added text ⁴ to state that the COG is evaluating surgery alone for patients with NLPHL with resection of a single, involved lymph node.

Primary Progressive/Recurrent Hodgkin Lymphoma in Children and Adolescents ⁵

Added text ⁶ to state that a positive PET scan prior to autologous HSCT is an adverse prognostic factors (cited Jabbour et al. as reference 17).

Late Effects from Childhood/Adolescent Hodgkin Lymphoma Therapy ⁷

Added text ⁸ to state that a study of 12 female childhood Hodgkin lymphoma survivors showed that VAMP chemotherapy and low dose involved-field radiation seems to have a minimum impact on fertitily (cited Donaldson et al. as reference 13).

Added text ⁹ to state that adding dexrazoxane in combination with etoposide in treating children with Hodgkin lymphoma remains controversial (cited Tebbi et al. and Cvetkovic et al. as references 45 and 46, respectively).

Added text ¹⁰ to state that there is controversy about the risk of treatment-related AML in Hodgkin lymphoma patients receiving dexrazoxane concurrent with etopisode (cited Le Deley et al. as reference 62).